US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

5.45

-0.1000-1.80%

Post-market: 5.640.1943+3.57%19:28 EST

Volume:669.34K

Turnover:3.65M

Market Cap:177.24M

PE:-3.05

High:5.60

Open:5.54

Low:5.31

Close:5.55

52wk High:11.41

52wk Low:1.73

Shares:32.52M

Float Shares:22.63M

Volume Ratio:0.65

T/O Rate:2.96%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.7861

EPS(LYR):-1.4535

ROE:-39.78%

ROA:-26.52%

PB:1.49

PE(LYR):-3.75

Loading ...

Overview Company News Filings

Sagimet Biosciences nimmt an Investorenkonferenzen von Guggenheim und Oppenheimer teil

After Clearing Up Acne, Sagimet Stock Rises -- Barrons.com

Wall Street's Top Analysts Issue Latest Ratings: Adobe Downgraded, Palantir Upgraded

Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.

Sagimet Biosciences initiated with a Buy at Guggenheim

Sagimet Biosciences price target raised to $37 from $29 at Clear Street

Analysts Conflicted on These Healthcare Names: Sagimet Biosciences, Inc. Class A (SGMT) and Siemens Healthineers AG (OtherSEMHF)

BRIEF-Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 Weeks

Sagimet Biosciences announces license partner Ascletis issues results for ASC40

Sagimet Biosciences Reports Positive 52-Week Phase 3 Results for Denifanstat in Moderate to Severe Acne

Sagimet Announces Positive 52-Week Data From License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of Asc40 (Denifanstat) Tablets in Patients With Moderate to Severe Acne

THOMSON REUTERS

Sagimet Biosciences Inc - Denifanstat Well Tolerated With Teaes Incidence Rate of 5% or More

THOMSON REUTERS

Sagimet Biosciences Inc - Denifanstat Shows Improvements in Efficacy Endpoints Beyond 12 Weeks

THOMSON REUTERS

Multiple Shots on Goal: Sagimet’s Differentiated MASH Combo and Acne Franchise Underpin Buy Rating and Favorable Risk‑Reward

Ascletis Pharma New Drug Application for Denifanstat Accepted by China National Medical Products Administration

Sagimet Biosciences Initiated at Equal-Weight by Barclays

Barclays Initiates Coverage on Sagimet Biosciences With Equal Weight Rating, $8 Price Target

MT Newswires Live

Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

Sagimet Biosciences Reports Positive Phase 1 Results for Denifanstat and Resmetirom Combination in MASH

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SGMT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"SGMT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGMT\",,,,,undefined,":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":5.45,"timestamp":1770670800000,"preClose":5.55,"halted":0,"volume":669344,"hourTrading":{"tag":"盘后","latestPrice":5.6443,"preClose":5.45,"latestTime":"19:28 EST","volume":1952,"amount":10805.8,"timestamp":1770683328504,"change":0.1943,"changeRate":0.035651,"amplitude":0.042532},"delay":0,"changeRate":-0.018018018018017955,"floatShares":22626486,"shares":32521599,"eps":-1.786134,"marketStatus":"Closed","change":-0.1,"latestTime":"02-09 16:00:00 EST","open":5.54,"high":5.602,"low":5.31,"amount":3649567.7717824,"amplitude":0.052613,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.786134,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":5,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":5.55,"preHourTrading":{"tag":"盘前","latestPrice":5.75,"preClose":5.55,"latestTime":"09:06 EST","volume":824,"amount":4675.3000272,"timestamp":1770645989262,"change":0.2,"changeRate":0.036036,"amplitude":0.028829},"postHourTrading":{"tag":"盘后","latestPrice":5.6443,"preClose":5.45,"latestTime":"19:28 EST","volume":1952,"amount":10805.8,"timestamp":1770683328504,"change":0.1943,"changeRate":0.035651,"amplitude":0.042532},"volumeRatio":0.651888,"impliedVol":0.7441,"impliedVolPercentile":0.0319},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SGMT\",,,,,undefined,":{"symbol":"SGMT","floatShares":22626486,"roa":"-26.52%","roe":"-39.78%","lyrEps":-1.453459,"volumeRatio":0.651888,"shares":32521599,"dividePrice":0,"high":5.602,"amplitude":0.052613,"preClose":5.55,"low":5.31,"week52Low":1.73,"pbRate":"1.49","week52High":11.41,"institutionHeld":0,"latestPrice":5.45,"eps":-1.786134,"divideRate":0,"volume":669344,"delay":0,"ttmEps":-1.786134,"open":5.54,"prevYearClose":5.92,"prevWeekClose":5.55,"prevMonthClose":5.67,"prevQuarterClose":5.92,"fiveDayClose":6.23,"twentyDayClose":6.21,"sixtyDayClose":8.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SGMT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"SGMT","fiscalQuarterEnding":"2025/09","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-0.4},{"market":"US","date":"2025-08-13","symbol":"SGMT","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-0.32},{"market":"US","date":"2025-05-08","symbol":"SGMT","fiscalQuarterEnding":"2025/03","expectedEps":-0.79,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.56}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SGMT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SGMT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6364,"hold":0.0909,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":11,"updateTime":1770354000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SGMT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SGMT","date":"2026-02-06","current":-3.051283,"percent":0.851613,"low":-15.666506,"twenty":-5.987575,"median":-4.238947,"eighty":-3.257919,"high":-1.342444,"avg":-4.926234,"sd":2.511912,"marketCap":176917498},"quantilePoints":[{"date":"2023-07-21","current":-12.287206,"twenty":-13.337015,"median":-12.553129,"eighty":-11.625533,"marketCap":348354576},{"date":"2023-07-28","current":-12.208993,"twenty":-12.714826,"median":-12.49838,"eighty":-12.113574,"marketCap":346137170},{"date":"2023-08-04","current":-12.733018,"twenty":-12.595364,"median":-12.529665,"eighty":-12.271563,"marketCap":360993794},{"date":"2023-08-11","current":-12.514023,"twenty":-12.565643,"median":-12.517933,"eighty":-12.42486,"marketCap":354785056},{"date":"2023-08-18","current":-9.925184,"twenty":-12.565643,"median":-12.514023,"eighty":-12.265307,"marketCap":281388897},{"date":"2023-08-25","current":-9.359416,"twenty":-12.554693,"median":-12.471006,"eighty":-10.020915,"marketCap":262381858},{"date":"2023-09-01","current":-9.85717,"twenty":-12.553129,"median":-12.459274,"eighty":-9.809842,"marketCap":276335907},{"date":"2023-09-08","current":-10.126447,"twenty":-12.543743,"median":-12.279385,"eighty":-9.775571,"marketCap":283884818},{"date":"2023-09-15","current":-9.791891,"twenty":-12.532793,"median":-11.532454,"eighty":-9.775571,"marketCap":274505868},{"date":"2023-09-22","current":-8.282308,"twenty":-12.524972,"median":-10.126447,"eighty":-9.674388,"marketCap":232186213},{"date":"2023-09-29","current":-7.392878,"twenty":-12.517151,"median":-9.936056,"eighty":-9.403479,"marketCap":207251930},{"date":"2023-10-06","current":-5.866975,"twenty":-12.514023,"median":-9.90613,"eighty":-8.80291,"marketCap":164474765},{"date":"2023-10-13","current":-4.757227,"twenty":-12.495252,"median":-9.80821,"eighty":-7.764969,"marketCap":133364100},{"date":"2023-10-20","current":-3.729078,"twenty":-12.478045,"median":-9.791891,"eighty":-6.978354,"marketCap":104540984},{"date":"2023-10-27","current":-3.647479,"twenty":-12.474916,"median":-9.751091,"eighty":-6.462648,"marketCap":102253435},{"date":"2023-11-03","current":-3.100765,"twenty":-12.467095,"median":-9.681732,"eighty":-5.866975,"marketCap":86926858},{"date":"2023-11-10","current":-2.284775,"twenty":-12.467095,"median":-9.514454,"eighty":-4.757227,"marketCap":64051369},{"date":"2023-11-17","current":-1.981702,"twenty":-12.459274,"median":-9.396135,"eighty":-4.030995,"marketCap":53347428},{"date":"2023-11-24","current":-3.487116,"twenty":-12.32162,"median":-9.116089,"eighty":-3.455541,"marketCap":93873157},{"date":"2023-12-01","current":-3.248971,"twenty":-12.280949,"median":-8.665823,"eighty":-3.326797,"marketCap":87462307},{"date":"2023-12-08","current":-3.436085,"twenty":-12.223071,"median":-7.870232,"eighty":-3.326797,"marketCap":92499403},{"date":"2023-12-15","current":-4.74588,"twenty":-11.827315,"median":-7.466317,"eighty":-3.305106,"marketCap":127759077},{"date":"2023-12-22","current":-4.79691,"twenty":-11.412789,"median":-6.927763,"eighty":-3.326797,"marketCap":129132830},{"date":"2023-12-29","current":-5.009539,"twenty":-10.856914,"median":-6.462648,"eighty":-3.351567,"marketCap":134856803},{"date":"2024-01-05","current":-4.286601,"twenty":-10.142767,"median":-6.27497,"eighty":-3.385054,"marketCap":115395295},{"date":"2024-01-12","current":-6.055674,"twenty":-10.126447,"median":-6.038333,"eighty":-3.402064,"marketCap":163018751},{"date":"2024-01-19","current":-5.494334,"twenty":-10.061168,"median":-5.928097,"eighty":-3.422477,"marketCap":147907462},{"date":"2024-01-26","current":-11.924235,"twenty":-11.412789,"median":-6.047003,"eighty":-3.434384,"marketCap":321000405},{"date":"2024-02-02","current":-11.8484,"twenty":-11.755197,"median":-6.332089,"eighty":-3.449693,"marketCap":318958920},{"date":"2024-02-09","current":-7.10904,"twenty":-11.755197,"median":-6.72671,"eighty":-3.480312,"marketCap":191375352},{"date":"2024-02-16","current":-10.260714,"twenty":-11.412789,"median":-7.18072,"eighty":-3.487116,"marketCap":276218424},{"date":"2024-02-23","current":-7.973973,"twenty":-11.272575,"median":-7.393401,"eighty":-3.512632,"marketCap":214659353},{"date":"2024-03-01","current":-7.263069,"twenty":-10.976358,"median":-7.495026,"eighty":-3.600344,"marketCap":195521817},{"date":"2024-03-08","current":-7.642218,"twenty":-10.478725,"median":-7.466317,"eighty":-3.696438,"marketCap":205728503},{"date":"2024-03-15","current":-5.118509,"twenty":-10.189946,"median":-7.39314,"eighty":-3.910228,"marketCap":137790253},{"date":"2024-03-22","current":-5.509506,"twenty":-10.132975,"median":-7.18072,"eighty":-4.056781,"marketCap":148315897},{"date":"2024-03-28","current":-6.56,"twenty":-10.093807,"median":-7.132737,"eighty":-4.084178,"marketCap":182866572},{"date":"2024-04-05","current":-6.239442,"twenty":-10.00568,"median":-6.795721,"eighty":-4.174333,"marketCap":173930684},{"date":"2024-04-12","current":-5.976126,"twenty":-9.938231,"median":-6.56,"eighty":-4.313817,"marketCap":166590490},{"date":"2024-04-19","current":-4.545061,"twenty":-9.925184,"median":-6.397368,"eighty":-4.392065,"marketCap":126698131},{"date":"2024-04-26","current":-4.487819,"twenty":-9.917562,"median":-6.217851,"eighty":-4.458405,"marketCap":125102437},{"date":"2024-05-03","current":-5.09459,"twenty":-9.886546,"median":-6.182199,"eighty":-4.468439,"marketCap":142016797},{"date":"2024-05-10","current":-5.231972,"twenty":-9.844114,"median":-6.079163,"eighty":-4.479356,"marketCap":145846463},{"date":"2024-05-17","current":-5.429865,"twenty":-9.811474,"median":-6.018678,"eighty":-4.487871,"marketCap":151590963},{"date":"2024-05-24","current":-5.372708,"twenty":-9.791891,"median":-5.987575,"eighty":-4.491214,"marketCap":149995268},{"date":"2024-05-31","current":-6.172899,"twenty":-9.791891,"median":-5.987575,"eighty":-4.501006,"marketCap":172334989},{"date":"2024-06-07","current":-5.315552,"twenty":-9.783731,"median":-5.976126,"eighty":-4.523122,"marketCap":148399574},{"date":"2024-06-14","current":-5.47559,"twenty":-9.751091,"median":-5.952111,"eighty":-4.533251,"marketCap":152867518},{"date":"2024-06-21","current":-4.446773,"twenty":-9.731508,"median":-5.91688,"eighty":-4.519544,"marketCap":124145020},{"date":"2024-06-28","current":-4.698262,"twenty":-9.718452,"median":-5.91688,"eighty":-4.523122,"marketCap":131166075},{"date":"2024-07-05","current":-3.257919,"twenty":-9.685812,"median":-5.888477,"eighty":-4.48795,"marketCap":90954577},{"date":"2024-07-12","current":-3.738033,"twenty":-9.677652,"median":-5.800519,"eighty":-4.448199,"marketCap":104358410},{"date":"2024-07-15","current":-3.806621,"twenty":-9.67602,"median":-5.796735,"eighty":-4.447058,"marketCap":106273243},{"date":"2024-08-02","current":-3.97809,"twenty":-9.674388,"median":-5.79295,"eighty":-4.391494,"marketCap":111060326},{"date":"2024-08-09","current":-3.109312,"twenty":-9.635837,"median":-5.632964,"eighty":-4.048186,"marketCap":86805772},{"date":"2024-08-16","current":-3.011259,"twenty":-9.556995,"median":-5.529634,"eighty":-3.765468,"marketCap":88082328},{"date":"2024-08-23","current":-3.174914,"twenty":-9.5049,"median":-5.509506,"eighty":-3.626007,"marketCap":92869411},{"date":"2024-08-30","current":-3.36039,"twenty":-9.480538,"median":-5.47559,"eighty":-3.517501,"marketCap":98294771},{"date":"2024-09-06","current":-2.913065,"twenty":-9.458966,"median":-5.429865,"eighty":-3.459899,"marketCap":85210078},{"date":"2024-09-13","current":-3.709522,"twenty":-9.418167,"median":-5.410329,"eighty":-3.440029,"marketCap":108507215},{"date":"2024-09-20","current":-3.578597,"twenty":-9.3382,"median":-5.372708,"eighty":-3.459899,"marketCap":104677549},{"date":"2024-09-27","current":-3.076721,"twenty":-9.217671,"median":-5.306102,"eighty":-3.426198,"marketCap":89997161},{"date":"2024-10-04","current":-4.495067,"twenty":-9.063099,"median":-5.281258,"eighty":-3.402458,"marketCap":131485214},{"date":"2024-10-11","current":-4.516888,"twenty":-9.008144,"median":-5.226248,"eighty":-3.408396,"marketCap":132123492},{"date":"2024-10-18","current":-5.891593,"twenty":-8.972181,"median":-5.273199,"eighty":-3.426198,"marketCap":172334989},{"date":"2024-10-25","current":-6.000697,"twenty":-8.935294,"median":-5.292689,"eighty":-3.429281,"marketCap":175526378},{"date":"2024-10-31","current":-5.826131,"twenty":-8.894301,"median":-5.311818,"eighty":-3.436085,"marketCap":170420156},{"date":"2024-11-08","current":-6.753511,"twenty":-8.791513,"median":-5.372708,"eighty":-3.436763,"marketCap":197546960},{"date":"2024-11-15","current":-5.651565,"twenty":-8.755967,"median":-5.41811,"eighty":-3.453095,"marketCap":165313934},{"date":"2024-11-22","current":-3.861691,"twenty":-8.665823,"median":-5.372708,"eighty":-3.487116,"marketCap":144879052},{"date":"2024-11-29","current":-4.882893,"twenty":-8.557843,"median":-5.315552,"eighty":-3.487116,"marketCap":183191513},{"date":"2024-12-06","current":-3.998995,"twenty":-8.332016,"median":-5.292689,"eighty":-3.504949,"marketCap":150030307},{"date":"2024-12-13","current":-3.896017,"twenty":-8.272608,"median":-5.273199,"eighty":-3.525595,"marketCap":146166866},{"date":"2024-12-20","current":-4.350838,"twenty":-8.042693,"median":-5.190447,"eighty":-3.550034,"marketCap":163230399},{"date":"2024-12-27","current":-4.35942,"twenty":-7.978712,"median":-5.107971,"eighty":-3.56885,"marketCap":163552352},{"date":"2025-01-03","current":-3.853109,"twenty":-7.96022,"median":-5.094591,"eighty":-3.578236,"marketCap":144557099},{"date":"2025-01-10","current":-4.608284,"twenty":-7.932249,"median":-5.088866,"eighty":-3.585335,"marketCap":172889002},{"date":"2025-01-17","current":-3.664315,"twenty":-7.891035,"median":-5.014451,"eighty":-3.578519,"marketCap":137474123},{"date":"2025-01-24","current":-3.561337,"twenty":-7.843641,"median":-5.001034,"eighty":-3.577995,"marketCap":133610681},{"date":"2025-01-31","current":-3.484103,"twenty":-7.800873,"median":-4.931489,"eighty":-3.565628,"marketCap":130713100},{"date":"2025-02-07","current":-4.041903,"twenty":-7.796247,"median":-4.899965,"eighty":-3.577995,"marketCap":151640074},{"date":"2025-02-14","current":-3.775875,"twenty":-7.711114,"median":-4.882893,"eighty":-3.5785,"marketCap":141659518},{"date":"2025-02-21","current":-3.454068,"twenty":-7.655997,"median":-4.848447,"eighty":-3.56477,"marketCap":129586263},{"date":"2025-02-28","current":-3.097934,"twenty":-7.585345,"median":-4.824006,"eighty":-3.534402,"marketCap":116225195},{"date":"2025-03-07","current":-3.13226,"twenty":-7.533213,"median":-4.786117,"eighty":-3.487116,"marketCap":117513009},{"date":"2025-03-14","current":-2.479989,"twenty":-7.4778,"median":-4.774032,"eighty":-3.471231,"marketCap":113005660},{"date":"2025-03-21","current":-2.861526,"twenty":-7.417463,"median":-4.751553,"eighty":-3.434384,"marketCap":130391147},{"date":"2025-03-28","current":-2.656626,"twenty":-7.395771,"median":-4.728869,"eighty":-3.400275,"marketCap":121054497},{"date":"2025-04-04","current":-1.603868,"twenty":-7.392983,"median":-4.702859,"eighty":-3.36039,"marketCap":73083433},{"date":"2025-04-11","current":-1.575606,"twenty":-7.289031,"median":-4.694849,"eighty":-3.31696,"marketCap":71795619},{"date":"2025-04-17","current":-1.42723,"twenty":-7.21366,"median":-4.648098,"eighty":-3.301626,"marketCap":65034596},{"date":"2025-04-25","current":-2.204435,"twenty":-7.173257,"median":-4.603993,"eighty":-3.254074,"marketCap":100449476},{"date":"2025-05-02","current":-2.77674,"twenty":-7.146955,"median":-4.575776,"eighty":-3.219588,"marketCap":126527705},{"date":"2025-05-09","current":-1.80385,"twenty":-7.118519,"median":-4.541885,"eighty":-3.18279,"marketCap":103025104},{"date":"2025-05-16","current":-1.865858,"twenty":-6.931314,"median":-4.533251,"eighty":-3.143037,"marketCap":106566591},{"date":"2025-05-23","current":-1.922228,"twenty":-6.7923,"median":-4.516125,"eighty":-3.120362,"marketCap":109786126},{"date":"2025-05-30","current":-1.972961,"twenty":-6.768572,"median":-4.505306,"eighty":-3.099066,"marketCap":112683707},{"date":"2025-06-06","current":-2.694501,"twenty":-6.722029,"median":-4.495067,"eighty":-3.076721,"marketCap":153893749},{"date":"2025-06-13","current":-4.853485,"twenty":-6.632098,"median":-4.487884,"eighty":-3.076721,"marketCap":277201920},{"date":"2025-06-20","current":-3.968471,"twenty":-6.566428,"median":-4.480766,"eighty":-3.076721,"marketCap":226655228},{"date":"2025-06-27","current":-4.904218,"twenty":-6.557243,"median":-4.495067,"eighty":-3.078851,"marketCap":280099501},{"date":"2025-07-03","current":-4.650551,"twenty":-6.546215,"median":-4.495067,"eighty":-3.087373,"marketCap":265611596},{"date":"2025-07-11","current":-5.586299,"twenty":-6.535304,"median":-4.505306,"eighty":-3.097934,"marketCap":319055868},{"date":"2025-07-18","current":-5.383366,"twenty":-6.492923,"median":-4.516888,"eighty":-3.100765,"marketCap":307465544},{"date":"2025-07-25","current":-5.749773,"twenty":-6.480752,"median":-4.529894,"eighty":-3.109312,"marketCap":328392519},{"date":"2025-08-01","current":-4.898581,"twenty":-6.480752,"median":-4.538709,"eighty":-3.120362,"marketCap":279777548},{"date":"2025-08-08","current":-5.101514,"twenty":-6.462648,"median":-4.566286,"eighty":-3.120362,"marketCap":291367872},{"date":"2025-08-15","current":-5.891315,"twenty":-6.437111,"median":-4.599703,"eighty":-3.13226,"marketCap":349838046},{"date":"2025-08-22","current":-4.025357,"twenty":-6.382559,"median":-4.566286,"eighty":-3.13419,"marketCap":239033752},{"date":"2025-08-29","current":-4.140367,"twenty":-6.360738,"median":-4.538709,"eighty":-3.140842,"marketCap":245863288},{"date":"2025-09-05","current":-3.97059,"twenty":-6.343282,"median":-4.533251,"eighty":-3.141915,"marketCap":235781592},{"date":"2025-09-12","current":-3.85558,"twenty":-6.333455,"median":-4.518739,"eighty":-3.143321,"marketCap":228952056},{"date":"2025-09-19","current":-3.696756,"twenty":-6.268752,"median":-4.505306,"eighty":-3.155125,"marketCap":219520793},{"date":"2025-09-26","current":-3.910347,"twenty":-6.242137,"median":-4.495589,"eighty":-3.161438,"marketCap":232204216},{"date":"2025-10-03","current":-3.9213,"twenty":-6.222169,"median":-4.487819,"eighty":-3.17239,"marketCap":232854648},{"date":"2025-10-10","current":-4.720895,"twenty":-6.216806,"median":-4.469318,"eighty":-3.185415,"marketCap":280336183},{"date":"2025-10-17","current":-4.134891,"twenty":-6.207386,"median":-4.448199,"eighty":-3.194996,"marketCap":245538072},{"date":"2025-10-24","current":-4.014404,"twenty":-6.179338,"median":-4.440945,"eighty":-3.205463,"marketCap":238383320},{"date":"2025-10-31","current":-4.458014,"twenty":-6.166061,"median":-4.448199,"eighty":-3.212557,"marketCap":264725815},{"date":"2025-11-07","current":-4.211564,"twenty":-6.160312,"median":-4.446004,"eighty":-3.221522,"marketCap":250091096},{"date":"2025-11-14","current":-4.238947,"twenty":-6.115309,"median":-4.446773,"eighty":-3.228264,"marketCap":251717176},{"date":"2025-11-21","current":-4.099669,"twenty":-6.104311,"median":-4.436499,"eighty":-3.233938,"marketCap":236432024},{"date":"2025-11-28","current":-4.071473,"twenty":-6.101058,"median":-4.420471,"eighty":-3.243405,"marketCap":234805944},{"date":"2025-12-05","current":-3.580867,"twenty":-6.095284,"median":-4.404184,"eighty":-3.254074,"marketCap":206512153},{"date":"2025-12-12","current":-3.569588,"twenty":-6.08465,"median":-4.372292,"eighty":-3.257742,"marketCap":205861721},{"date":"2025-12-19","current":-3.360939,"twenty":-6.079163,"median":-4.354642,"eighty":-3.257919,"marketCap":193828730},{"date":"2025-12-26","current":-3.417331,"twenty":-6.078325,"median":-4.333675,"eighty":-3.272875,"marketCap":197080889},{"date":"2026-01-02","current":-3.338383,"twenty":-6.07279,"median":-4.295418,"eighty":-3.296029,"marketCap":192527866},{"date":"2026-01-09","current":-3.141012,"twenty":-6.052206,"median":-4.275812,"eighty":-3.257565,"marketCap":181145306},{"date":"2026-01-16","current":-3.530114,"twenty":-6.030806,"median":-4.260854,"eighty":-3.257919,"marketCap":203585209},{"date":"2026-01-23","current":-3.580867,"twenty":-6.000697,"median":-4.24786,"eighty":-3.257919,"marketCap":206512153},{"date":"2026-01-30","current":-3.02259,"twenty":-5.999023,"median":-4.239278,"eighty":-3.257919,"marketCap":174315770},{"date":"2026-02-06","current":-3.067703,"twenty":-5.987575,"median":-4.238947,"eighty":-3.257919,"marketCap":176917498}],"updateTime":1770697312067},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SGMT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609374299","title":"Sagimet Biosciences nimmt an Investorenkonferenzen von Guggenheim und Oppenheimer teil","url":"https://stock-news.laohu8.com/highlight/detail?id=2609374299","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609374299?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:00","pubTimestamp":1770292843,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc. wird am 11. Februar 2026 am Guggenheim Emerging Outlook: Biotech Summit in New York teilnehmen und am 26. Februar 2026 beim Oppenheimer 36th Annual Healthcare Life Sciences Conference vertreten sein.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL2BfTWH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014039.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014005.SGD","BK4139","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","LU2210150020.SGD","SG9999014021.USD","BK4112","SGMT","BK4588"],"gpt_icon":0},{"id":"2608807643","title":"After Clearing Up Acne, Sagimet Stock Rises -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2608807643","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608807643?lang=en_us&edition=fundamental","pubTime":"2026-02-04 04:27","pubTimestamp":1770150420,"startTime":"0","endTime":"0","summary":"Shares of Sagimet Biosciences were up as much as 12% Tuesday morning, on encouraging clinical trial results for its acne treatment and a new Buy recommendation from Guggenheim Securities.For much of its history, the San Mateo, Calif-based firm played up the promise of its novel drug for treating liver diseases brought on by obesity. But lately, it is drawing attention for those drugs' success at clearing a more familiar affliction: acne.The news helped lift Sagimet stock Tuesday to $7.20 and bring the little company's market cap to $230 million. That is well below the $16 level where Sagimet came public in 2023. But in a Tuesday note launching coverage on the company, Guggenheim's Seamus Fernandez says the stock can rise as high as $27, if either the liver or acne drug reach his expectations.If approved and launched by 2030, he thinks the drug's sales as a first line treatment for acne could surpass a billion dollars. The existing treatments include generic versions of the Roche drug A","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01672","BK1515","BK4139","SGMT","BK1161"],"gpt_icon":0},{"id":"1119251824","title":"Wall Street's Top Analysts Issue Latest Ratings: Adobe Downgraded, Palantir Upgraded","url":"https://stock-news.laohu8.com/highlight/detail?id=1119251824","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119251824?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:54","pubTimestamp":1770130488,"startTime":"0","endTime":"0","summary":"Here is a summary of the latest analyst ratings from Wall Street that are most closely watched and have significant market impact. The following are today's key rating changes compiled by The Fly...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109391861.USD","LU0965509010.AUD","LU2125154935.USD","LU2023251221.USD","LU2089283258.USD","LU0708995401.HKD","LU1366333091.USD","LU2357305700.SGD","LU0557290698.USD","TASK","DIS","LU1674673691.USD","LU1119994496.HKD","LU2458330169.SGD","LU0345774631.USD","LU0957791311.USD","LU2089284900.SGD","LU0889566641.SGD","LU1261432733.SGD","LU0158827948.USD","IE00B5TLWC47.USD","LU0069063385.USD","LU2360032135.SGD","LU0511384066.AUD","LU1691799644.USD","LU1823568750.SGD","FIGR","LU0868494708.USD","BK4533","SGMT","IE00BQXX3D17.EUR","PLTR","BK4554","LU0719512351.SGD","LU2317271919.USD","BK4585","LU2210149790.SGD","LU1046421795.USD","LU0861579265.USD","IE00BFXG0V08.USD","LU0061474960.USD","LU0965509101.SGD","LU0081259029.USD","BK4527","LU0314104364.USD","LU0342679015.USD","LU1674673428.USD","IE0009356076.USD","LU1712237335.SGD","LU1235294995.USD","LU1778281490.HKD","LU1623119135.USD","LU1720051108.HKD","LU0106261372.USD","BK4592","LU0868494617.USD","BK4023","LU1548497426.USD","LU0672654240.SGD","LU1815333072.USD","AFRM","BK4534","LU1720051017.SGD","V","LU1267930730.SGD","SGXZ51526630.SGD","XOM","LU0057025933.USD","AKTS","LU0348723411.USD","LU0006306889.USD","LU0942090050.USD","LU0109392836.USD","IE00B19Z9505.USD","LU0289961442.SGD","MA","BK4588","LU0345774391.USD","SGXZ81514606.USD","BK4567","BK4528","LU2125154778.USD","IE00BYQQ9H92.USD","LU2095319765.USD","LU0289739343.SGD","STAA","LU2210150020.SGD","LU0965509283.SGD","LU1803068979.SGD","LU0320765059.SGD","SGXZ99366536.SGD","LU1267930813.SGD","LU1633808545.USD","ADBE","LU0234572021.USD","QTWO","ELV","JBLU","LU0198837287.USD","SG9999001424.SGD","CTRA","LU0170899867.USD","LU1084165304.USD","LU0472753341.HKD","BK4566","BK4543","IE00BQXX3C00.GBP","LU2458330243.SGD","LU0889565833.HKD","LU2236285917.USD","BK4581","IE00BQXX3F31.USD","LU0234570918.USD","LU2237438978.USD","SG9999000418.SGD","LU0792757196.USD","LU0082616367.USD","LU0157215616.USD"],"gpt_icon":1},{"id":"2608876857","title":"Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2608876857","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608876857?lang=en_us&edition=fundamental","pubTime":"2026-02-03 20:39","pubTimestamp":1770122340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 03, 2026 07:39 ET (12:39 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2608759688","title":"Sagimet Biosciences initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2608759688","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608759688?lang=en_us&edition=fundamental","pubTime":"2026-02-03 20:21","pubTimestamp":1770121267,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Seamus Fernandez initiated coverage of Sagimet Biosciences (SGMT) with a Buy rating and $27 price target The firm believes the c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-a-buy-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-a-buy-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2608482288","title":"Sagimet Biosciences price target raised to $37 from $29 at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2608482288","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608482288?lang=en_us&edition=fundamental","pubTime":"2026-02-03 18:20","pubTimestamp":1770114010,"startTime":"0","endTime":"0","summary":"Clear Street raised the firm’s price target on Sagimet Biosciences (SGMT) to $37 from $29 and keeps a Buy rating on the shares. The firm says the 5...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-raised-to-37-from-29-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-raised-to-37-from-29-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2608982333","title":"Analysts Conflicted on These Healthcare Names: Sagimet Biosciences, Inc. Class A (SGMT) and Siemens Healthineers AG (OtherSEMHF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608982333","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608982333?lang=en_us&edition=fundamental","pubTime":"2026-02-03 15:51","pubTimestamp":1770105066,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sagimet Biosciences, Inc. Class A (SGMT – Research...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-sagimet-biosciences-inc-class-a-sgmt-and-siemens-healthineers-ag-othersemhf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-sagimet-biosciences-inc-class-a-sgmt-and-siemens-healthineers-ag-othersemhf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4581","SGMT","AG","BK4585","LABU","LU0128526141.USD","BK4588","BK4210","HCSG","BK4139","XLV","BK4137","LU0029874061.USD"],"gpt_icon":0},{"id":"2608886622","title":"BRIEF-Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2608886622","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608886622?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:24","pubTimestamp":1770035075,"startTime":"0","endTime":"0","summary":"BRIEF-Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 WeeksFeb 2 (Reuters) - Sagimet Biosciences Inc SGMT.O:SAGIMET ANNOUNCES POSITIVE 52-WEEK DATA FROM LICENSE PARTNER ASC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA5XCTVT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2608662988","title":"Sagimet Biosciences announces license partner Ascletis issues results for ASC40","url":"https://stock-news.laohu8.com/highlight/detail?id=2608662988","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608662988?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:21","pubTimestamp":1770034862,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) announced that Ascletis Pharma issued a press release on January 29th reporting positive topline results in the open-lab...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-announces-license-partner-ascletis-issues-results-for-asc40-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-announces-license-partner-ascletis-issues-results-for-asc40-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2608657558","title":"Sagimet Biosciences Reports Positive 52-Week Phase 3 Results for Denifanstat in Moderate to Severe Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2608657558","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608657558?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033629,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc. announced positive 52-week data from an open-label Phase 3 clinical trial conducted by its license partner, Ascletis Pharma Inc., evaluating the long-term safety of ASC40  tablets in patients with moderate to severe acne. The topline results from this trial were reported in a press release issued by Ascletis on January 29. Denifanstat is an oral fatty acid synthase  inhibitor developed by Ascletis for acne in China and by Sagimet for MASH in other regions. In June 2025, Ascletis also reported that denifanstat met all primary, key secondary, and secondary endpoints in a separate 480-patient randomized, double-blind, placebo-controlled Phase 3 trial for moderate to severe acne vulgaris. Results from both studies have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDLc00t16:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","SG9999014013.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","BK1515","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4112","BK4139","SG9999014039.USD","BK1161","SGMT","BK1574","LU2210149790.SGD","01672","BK4588","NDAQ","IE00BGHQF748.EUR","LU2095319765.USD"],"gpt_icon":0},{"id":"2608865264","title":"Sagimet Announces Positive 52-Week Data From License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of Asc40 (Denifanstat) Tablets in Patients With Moderate to Severe Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2608865264","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608865264?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA5XCTVT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2608657758","title":"Sagimet Biosciences Inc - Denifanstat Well Tolerated With Teaes Incidence Rate of 5% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2608657758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608657758?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA5XCTVT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2608186577","title":"Sagimet Biosciences Inc - Denifanstat Shows Improvements in Efficacy Endpoints Beyond 12 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2608186577","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608186577?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA5XCTVT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2608887077","title":"Multiple Shots on Goal: Sagimet’s Differentiated MASH Combo and Acne Franchise Underpin Buy Rating and Favorable Risk‑Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887077","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608887077?lang=en_us&edition=fundamental","pubTime":"2026-02-02 08:15","pubTimestamp":1769991324,"startTime":"0","endTime":"0","summary":"Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on Sagimet Biosciences, Inc. Class A, retaining the price target of $26.00. De...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/multiple-shots-on-goal-sagimets-differentiated-mash-combo-and-acne-franchise-underpin-buy-rating-and-favorable-risk‑reward-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/multiple-shots-on-goal-sagimets-differentiated-mash-combo-and-acne-franchise-underpin-buy-rating-and-favorable-risk‑reward-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2607832600","title":"Ascletis Pharma New Drug Application for Denifanstat Accepted by China National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2607832600","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607832600?lang=en_us&edition=fundamental","pubTime":"2026-01-29 18:51","pubTimestamp":1769683870,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. announced that its New Drug Application  for denifanstat , a first-in-class, once-daily oral fatty acid synthase  inhibitor for the treatment of moderate-to-severe acne vulgaris, was recently accepted by the China National Medical Products Administration. The acceptance follows positive topline results from two Phase III studies, including a recently completed open-label multicenter study in China evaluating the long-term safety of denifanstat in 240 patients. Denifanstat  is licensed from Sagimet Biosciences Inc. for exclusive rights in Greater China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL1NxTbV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","BK1161","SGMT","BK4139","01672"],"gpt_icon":0},{"id":"2606102007","title":"Sagimet Biosciences Initiated at Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2606102007","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606102007?lang=en_us&edition=fundamental","pubTime":"2026-01-28 23:00","pubTimestamp":1769612400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 10:00 ET (15:00 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2606198317","title":"Barclays Initiates Coverage on Sagimet Biosciences With Equal Weight Rating, $8 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2606198317","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606198317?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:43","pubTimestamp":1769604213,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) has an average rating of Buy and mean price target of $26, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGMT"],"gpt_icon":0},{"id":"2602305637","title":"Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2602305637","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602305637?lang=en_us&edition=fundamental","pubTime":"2026-01-10 02:35","pubTimestamp":1767983740,"startTime":"0","endTime":"0","summary":"In a report released today, Debanjana Chatterjee from JonesTrading maintained a Buy rating on Sagimet Biosciences, Inc. Class A, with a price targe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sagimet-biosciences-advancing-fasn-inhibitor-pipeline-and-multi-indication-opportunities-support-buy-rating-and-26-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sagimet-biosciences-advancing-fasn-inhibitor-pipeline-and-multi-indication-opportunities-support-buy-rating-and-26-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2601369845","title":"Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369845","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369845?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873600,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Jan.  08, 2026  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215214/0/en/Sagimet-Biosciences-Announces-Poster-Presentation-at-the-10th-Annual-MASH-TAG-2026-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2592490843","title":"Sagimet Biosciences Reports Positive Phase 1 Results for Denifanstat and Resmetirom Combination in MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2592490843","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592490843?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:00","pubTimestamp":1766059216,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc. announced positive results from a Phase 1 pharmacokinetic  clinical trial evaluating the combination of its oral fatty acid synthase  inhibitor, denifanstat, with the thyroid hormone receptor beta  agonist, resmetirom. The study enrolled 40 healthy adult participants and assessed the safety, tolerability, and potential drug-drug interactions of the combination. The results indicated that the combination was generally well-tolerated, with no serious adverse events or treatment discontinuations reported. These Phase 1 results have already been presented, and Sagimet plans to advance the combination into a Phase 2 proof-of-concept efficacy trial for patients with metabolic dysfunction-associated steatohepatitis  with F4 fibrosis, expected to initiate in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL50FP5d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","BK4112","IE00B3QW5Z07.USD","BK4139","LU0314104364.USD","LU2095319765.USD","NDAQ","SG9999014039.USD","SG9999014021.USD","LU2210149790.SGD","SG9999014013.SGD","SGMT","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":79,"code":"91000000","status":"200"}]}}